The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

The FDA has approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have previously received one to three systemic treatment regimens.

The FDA has approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have previously received one to three systemic treatment regimens.

The FDA has approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have previously received one to three systemic treatment regimens.